UK pharma firm Clinigen Group plc has opened an office in Tokyo and set up Clinigen KK, a move to strengthen its presence in Asia after the acquisition of Asia and Africa focused pharma firm Link Healthcare last year.
Announcing the launch of its business in Japan in a statement today, Clinigen said that alongside the launch, Clinigen KK will transfer the marketing authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir® (foscarnet sodium) back from its Japanese distribution partner Nobel Pharma on November 1.
